(Q44279405)

1 December 2017

Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein (English)

1 reference

1 December 2017

Niels W C J van de Donk

series ordinal

1

object named as

van de Donk NW

1 reference

1 December 2017

6

Lokhorst HM

1 reference

1 December 2017

5

Bloem AC

1 reference

1 December 2017

Kamphuis MM

2

1 reference

PubMed ID

12529680

1 December 2017

van Dijk M

series ordinal

3

1 reference

PubMed ID

12529680

1 December 2017

Borst HP

series ordinal

4

1 reference

1 December 2017

1 January 2003

1 reference

1 December 2017

1 reference

1 December 2017

17

1 reference

1 December 2017

211-219

1 reference

1 December 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2402768

1 December 2017

0 references

cites work

Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

Levels of expression of the mdr1 gene and glutathione S-transferase genes 2 and 3 and response to chemotherapy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

Molecular signals in anti-apoptotic survival pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

Ras oncogene mutation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

Myeloid cell factor-1 is a critical survival factor for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl-2 oncoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

Expression of Bcl-2 family of proteins in fresh myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

BCL-2 family members and the mitochondria in apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

Mitochondrial control of cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

The mononucleotide-dependent, nonantisense mechanism of action of phosphodiester and phosphorothioate oligonucleotides depends upon the activity of an ecto-5'-nucleotidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

21 January 2018

Does antisense exist?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

Expressions of DNA topoisomerase I and II gene and the genes possibly related to drug resistance in human myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

7 January 2021

Interleukin-6 inhibits apoptosis of malignant plasma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

7 January 2021

Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

7 January 2021

Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

7 January 2021

bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

7 January 2021

BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402768

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2402768

1 reference

1 December 2017

1 reference

PubMed ID

12529680